LipoScience
LipoScience is a highly innovative, diagnostic company focused on changing the way heart disease, diabetes* and other metabolic diseases are assessed and managed.
We develop proprietary tests based on Nuclear Magnetic Resonance (NMR), an information-rich technology that produces a digital representation of the molecules present in a simple blood sample.
Over 7 million tests performed since 1999 to benefit physicians and their patients. This test directly measures lipoprotein particles and provides physicians and their patients more information to manage their risk for heart disease and diabetes.
The company is preparing to decentralize its proprietary platform with a broad array of high value NMR based assays, in support of driving toward new clinical standards of care.
We have broad opportunities for growth in our diagnostic, research, and laboratory businesses. We are actively pursuing these opportunities with the support of our employees, our customers, and our industry partners.
* The LP-IR test is only available through the LipoScience laboratory.
News
-
April 26, 2012
LipoScience receives 2012 Diagnostic Marketing Association Creative Communications First Place Award -
April 19, 2012
LipoScience announces exclusive license from Cleveland Clinic. -
March 19, 2012
LipoScience launches new medical education website devoted to lipoprotein particles in cardiovascular disease -
February 1, 2012
LipoScience surpasses seven million NMR LipoProfile tests ordered -
January 5, 2012
LipoScience submits FDA 510(K) for Vantera® Clinical Analyzer. Click here to view the press release. -
October 6, 2011
Published opinion of National Lipid Association expert panel advises testing of LDL particle number to assess and manage cardiovascular risk. Click here to view the press release





